Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature

• Published in: Disease markers 2014-01, Vol.2014 (2014), p.1-11
• Main Authors: Li, Chang-Hai, Liu, Ping, Xiong, Zhi-Fan, Liu, Xiang-Jie, Huang, Zao-Zao, Fang, Xiefan, Yang, Sheng-Li, Yao, Hong-Yi
• Format: Article
• Language: English
• Subjects: Biological markers; Biomarkers, Tumor - blood; Cancer; Carcinoma, Hepatocellular - blood; Carcinoma, Hepatocellular - diagnosis; Case-Control Studies; Diagnosis; Glypicans - blood; Hepatoma; Humans; Liver Neoplasms - blood; Liver Neoplasms - diagnosis; Oncology, Experimental; Review
• ISSN: 0278-0240; 1875-8630
• DOI: 10.1155/2014/127831

This review is to evaluate the diagnostic value of serum GPC3 for hepatocellular carcinoma (HCC) due to conflicting results reported. Methods. NCBI PubMed and Embase were comprehensively searched for studies that have used serum GPC3 level as a diagnostic index for HCC. The quality of the included studies was assessed. Subgroup analyses were conducted to evaluate the sensitivity and specificity of GPC3 as a HCC marker. Statistical analysis was performed with the software STATA version 12.0. Results. A total of 22 studies were included. The qualities of included studies were relatively poor. Among them, 18 studies have shown that serum GPC3 is a specific biomarker for HCC, and the pooled sensitivity and specificity of these studies were 69 and 93%, respectively. The other 4 studies have reported conflicting results, which were not caused by races, infection status of HBV and HCV, or assay reagents but due to one common experimental design of enrolling liver cirrhosis patients as control subjects. Conclusions. This meta-analysis indicates that serum GPC3 is elevated in HCC patients compared with healthy individuals, but more studies are needed to evaluate its effectiveness to differentially diagnose HCC and liver cirrhosis.